American Society of Hematology Annual Meeting and Exposition
|Several NCIC CTG abstracts will be presented at the 50th ASH Annual Meeting and Exposition
being held December 6-9, 2008 in San Francisco, California.
Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: Long-term outcome of the EORTC 20981 phase III randomized intergroup study
Marinus H.J. Van Oers, Martine Van Glabbeke, Liliana Baila, Livia Giurgia, Richard Klasa, Robert E Marcus, Max Wolf, Eva Kimby and Anton Hagenbeek.
Tuesday, December 9, 2008: 8:00 AM
NCIC CTG LY.7
The addition of rituximab eliminates the negative prognostic impact of PMBCL compared to DLBCL in young patients with CD20-positive aggressive lymphomas receiving a CHOP-like chemotherapy: Results of a subgroup analysis of the Mabthera International Trial Group (MInT) study
Marek Trneny, Michael Rieger, Anders Osterborg, Ruth Pettengel, Darrell J White, Devinder Gill, Jan Walewski, MD, Evelyn Kuhnt, Markus Loeffler, Michael Pfreundschuh, and Anthony D. Ho.
Tuesday, December 9, 2008: 8:45 AM
NCIC CTG MY.9
Phase II testing of lenalidomide plus melphalan for previously untreated older patients with multiple myeloma: The NCIC CTG MY.11 trial
Darrell J White, Nizar J Bahlis, Deborah C Marcellus, Andrew Belch, A. Keith Stewart, Christine Chen, Michael J Kovacs, David A Macdonald, Donna E Reece, Erica Harnett, Judy-Anne W Chapman, and Ralph M Meyer.
Sunday, December 7, 2008, 6:00 PM-8:00 PM
Tolerability and efficacy of bortezomib added to CVP-R for previously untreated advanced stage follicular lymphoma: Interim analysis of a phase II study by the NCIC Clinical Trials Group
Laurie H Sehn, David A Macdonald, Sheldon H. Rubin, Morel Rubinger, Kevin R Imrie, Judy-Anne W Chapman, Marina Djurfeldt, Lois Shepherd, Stephen Couban, and Michael Crump.
NCIC CTG LY.13
Saturday, December 6, 2008, 5:30 PM-7:30 PM
50th ASH Annual Meeting and Exposition
December 6-9, 2008
San Francisco, CA